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Abstract
Introduction: Forkhead box p3 (FoxP3)-expressing regulatory T cells (Tregs) have been clearly implicated in the 
control of autoimmune disease in murine models. In addition, ectopic expression of FoxP3 conveys a Treg phenotype 
to CD4+ T cells, lending itself to therapeutic use in the prevention of rheumatoid arthritis (RA). In this study, we 
generated therapeutically active Tregs with an increased life span and hence greater therapeutic potential.
Methods: We used retrovirus-mediated transduction to introduce FoxP3 or FoxP3 with anti-apoptotic Bcl-2 family 
molecule Bcl-xL linked by a 2A picornavirus self-cleaving peptide into CD4+ T cells to generate Tregs. In addition, by 
using in vitro functional analyses and adoptive immunotherapy in a murine model of RA, we demonstrated that these 
Tregs were highly reactive.
Results: We found that CD4+ T cells expressing both FoxP3 and Bcl-xL were able to differentiate into functional Tregs, 
which have a long-term survival advantage over cells transduced with FoxP3 alone. In an in vivo murine model, 
adoptive transfer of Tregs expressing both FoxP3 and Bcl-xL demonstrated more effective suppression of RA than CD4+ 
T cells expressing FoxP3 alone.
Conclusions: FoxP3 and Bcl-xL can cooperatively promote the differentiation and persistence of Tregs, with the 
capacity to prevent arthritis. Our results provide a novel approach for generating highly reactive Tregs for augmenting 
cellular immunotherapy for autoimmune disease.
Introduction
Regulatory T cells (Tregs) are a specialized subpopulation
of T cells that act to suppress activation of the immune sys-
tem and thereby maintain immune system homeostasis
and tolerance to self-antigens. Tregs are defined by expres-
sion of the forkhead family transcription factor FoxP3
(forkhead box p3), and CD4+CD25+FoxP3+  Tregs are
referred to as 'naturally occurring' Tregs [1]. Tregs com-
prise about 5% to 10% of the mature CD4+ helper T-cell
subpopulation in mice and about 1% to 2% of CD4+ T cells
in humans. It has been shown that functional Tregs can be
generated from naive CD4+ T cells by gene transduction of
FoxP3 [2-4]. The presence of transforming growth factor-
beta 1 (TGF-β1), interleukin-10 (IL-10), and IL-35 is also
required for maximal suppressive activity of Tregs [5-7].
However, the mechanisms by which Tregs exert their sup-
pressor/regulatory activity have not been fully character-
ized and are the subject of intensive research.
T-cell receptor (TCR) engagement or co-stimulatory
signals (for example, CD28) or both lead to expression of
several Bcl-2 family members, including Bcl-xL, Bcl-2,
and Bfl-1, which control T-cell survival [8,9]. In addition,
these signals modulate expression of FoxP3, which con-
trols differentiation of Tregs [10-13]. Previously, we dem-
onstrated that retrovirus-mediated transduction of target
genes of co-stimulation (for example, Bcl-xL, IKKβ
[inhibitor of kappaB kinase beta], survivin, and aurora B)
could promote T-cell functions [14-17]. Therefore, we
hypothesize that gene transduction of naive CD4+ T cells
with FoxP3 and Bcl-xL can induce the generation of
highly reactive Tregs, which may be used in the treatment
of autoimmune disease.
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Recent strategies have used the foot-and-mouth disease
virus 2A or 2A-like elements to create multicistronic vec-
t o r s  c a p a b l e  o f  g e n e r a t i n g  m u l t i p l e  p r o t e i n s  f r o m  t h e
same transcript. We previously demonstrated that a sin-
gle 2A peptide-linked retroviral vector can be used suc-
cessfully to generate reliable and versatile gene therapy
vectors that can be used in biomedical research [18]. To
understand whether FoxP3 and Bcl-xL can cooperatively
regulate differentiation and survival of Tregs, we used
retrovirus-mediated transduction to introduce FoxP3 and
Bcl-xL linked by a 2A peptide into naive CD4+ T cells. We
found that co-expression of FoxP3 and Bcl-xL in CD4+
cells is critical for augmenting the differentiation and per-
sistence of Tregs. Most significantly, the co-introduction
of these molecules into CD4+ T cells resulted in their abil-
ity to significantly block the development of arthritis in a
well-established murine model. Thus, these data indicate
that FoxP3 and Bcl-xL can cooperatively promote differ-
entiation and function of Tregs. Furthermore, genetic
modification with FoxP3 and Bcl-xL using vectors con-
taining the 2A sequence is able to generate highly reactive
Tregs that could be used for augmented cellular immuno-
therapy for autoimmune disease.
Materials and methods
Mice
DAB/1J and C57BL/6J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). OT-II TCR-
transgenic mice, expressing a TCR composed of variable
(Vβ5 and Vα2) chains responsive to the I-Ab-restricted
ovalbumin (OVA) peptide 323-339 (ISQAVHAAHAEIN-
AGR), were maintained by breeding with C57BL/6J mice.
All experiments were in compliance with the regulations
of the Pennsylvania State University College of Medicine
A n i m a l  C a r e  C o m m i t t e e  a n d  w e r e  i n  a c c o r d a n c e  wi t h
guidelines of the Association for the Assessment and
Accreditation of Laboratory Animal Care.
Antibodies
Anti-CD28 (37.51), mouse IL-2, and interferon-gamma
( I F N - γ )  w e r e  f r o m  B D  P h a r m i n g e n  ( S a n  D i e g o ,  C A ,
USA). Anti-actin (C2, sc-8432) for Western blot was pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Anti-Bcl-xL (#2762), peroxidase-conjugated
anti-rabbit (#7054), and anti-mouse Ig (#7056) for West-
ern blot were purchased from Cell Signaling Technology
(Beverly, MA, USA). All FITC (fluorescein isothiocya-
nate)-, PE (phycoerythrin)-, Cy5 (cyanine 5)-, and APC
(antigen-presenting cell)-conjugated antibodies were
purchased from BioLegend (San Diego, CA, USA).
T cells
Naive CD4+ T cells from spleen and lymph nodes of OT-
II mice were enriched by magnetic sorting with the CD4+
T Cell Isolation Kit (#130-090-860; Miltenyi Biotec Inc.,
Auburn, CA, USA). The cells were more than 90% CD4+,
and more than 95% of these cells expressed a naive phe-
notype and the appropriate TCR as determined by flow
cytometry at the Penn State Hershey flow cytometry core
facility.
T-cell cultures
T cells were cultured in 24-well plates containing 1 mL of
RPMI 1640 (Invitrogen Corporation, Carlsbad, CA, USA)
with 10% fetal calf serum (HyClone, Logan, UT, USA).
Naive CD4+ T cells were stimulated with plate-bounded
anti-CD3 (2C11, 4 μg/mL) and soluble anti-CD28 (37.51,
4 μg/mL) antibodies.
Retrovirus-mediated transduction
cDNA corresponding to human Bc1xL was subcloned
into the murine bicistronic retroviral expression vector
Mig [18]. Mig-FoxP3 was a gift from Alexander Y Ruden-
sky (Department of Immunology, University of Washing-
ton, Seattle, WA, USA) [19]. Retrovirus-mediated
transduction was performed as described previously [16].
Briefly, T cells (1 × 106) were stimulated with plate-
bounded anti-CD3 and soluble anti-CD28 antibodies.
After 2 days, the supernatant was replaced with 1 mL of
viral supernatant containing 5 μg/mL Polybrene (Sigma-
Aldrich, St. Louis, MO, USA), and the cells were sedi-
mented by centrifugation for 1.5 hours at 32°C and incu-
bated at 32°C for 8 hours. This step was repeated the
following day. Viral supernatant was removed and
replaced with fresh medium, and T cells were re-cultured.
Expression of green fluorescent protein (GFP) in CD4+ T
cells, indicative of retrovirus-mediated transduction, was
determined by flow cytometry. GFP-expressing T cells
were purified by cell sorting using a MoFlo high-perfor-
mance cell sorter (Beckman Coulter, Fullerton, CA,
USA).
Collagen-induced arthritis
Male DBA/1J mice (greater than 4 months of age) were
injected at the base of the tail with 0.1 mL of emulsion
containing 100 μg of bovine type II collagen (CII) (Chon-
drex, Redmond, WA, USA) in complete Freund's adju-
vant (CFA) (Chondrex) using a 1-mL glass tuberculin
syringe with a 26-guage needle. Mice were assessed for
clinical arthritis in the paws, with each paw individually
scored using a 4-point scale: 0, normal paw; 1, minimal
swelling or redness; 2, redness and swelling involving the
entire forepaw; 3, redness and swelling involving the
entire limb; 4, joint deformity or ankylosis or both. Ani-
mals achieving a clinical score of 4 were euthanized.
Histological evaluation
Mice were sacrificed on day 60 after the challenge of CII.
Hind foot paws were amputated, fixed in 10% formalin,Haque et al. Arthritis Research & Therapy 2010, 12:R66
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and decalcified in Formical-4 (Decal Chemical Corpora-
tion, Tallman, NY, USA). The tissues were embedded in
paraffin, sectioned at 4 μm, and stained with hematoxylin
and eosin (HE) or Safranin O-fast green as described
before [20]. HE staining for bone erosions was scored
using a semiquantitative scoring system from 0 to 4 (0 =
no erosions, 4 = extended erosions and destruction of
bone). Safranin O staining for the loss of proteoglycans
was scored with a semiquantitative scoring system (0 to
3), where 0 represents no loss of proteoglycans and 3
indicates complete loss of staining for proteoglycans.
Antibody detection
Blood samples were collected from the orbital sinus or by
heart puncture on day 60 after primary immunization
with CII. Total IgG was measured using the Easy-Titer
IgG Assay Kit (Pierce, Rockford, IL, USA) in accordance
with the recommendations of the manufacturer. The lev-
els of anti-CII IgG in these sera were measured by
enzyme-linked immunosorbent assay (ELISA) as
described before [21]. Briefly, a 96-well microplate
(Nunc, Roskilde, Denmark) was coated with 5 μg/mL CII
at 4°C overnight followed by blocking with 0.2% bovine
serum albumin and 0.05% Tween-20 in phosphate-buff-
ered saline (PBS) at 4°C for 6 hours. Test samples were
appropriately diluted with PBS containing 2% normal
goat serum and added at 200 μL/well. After storage at 4°C
overnight, wells were washed three times with PBS. Next,
100 μL of 1:1,000-diluted rabbit anti-mouse IgG1 or
IgG2a conjugated with biotin and 100 μL of streptavvi-
din-peroxidase secondary antibody (Rockland Immuno-
chemicals Inc., Gilbertsville, PA, USA) was added to each
well and incubated at 4°C for 2 hours and 1 hour, respec-
tively. After thorough washing, bound peroxidase activity
was assayed by incubating samples at room temperature
with 100 μL of TMB (3,3',5,5' tetramethylbenzidine) sub-
strate (BioLegend). Absorbance at 405 nm was measured
using a microplate reader.
Adoptive cell transfer
T cells were cultured with CD3/CD28 and transduced on
day 2/3 with retroviral vectors as described previously
[16]. Cells were recultured for 3 more days. GFP+ CD4+ T
cells were sorted by a MoFlo high-performance cell
sorter, and 2.5 × 106 cells were injected intravenously into
the tail vein of male DBA/1J mice that had been induced
to develop collagen-induced arthritis (CIA) 15 days prior
by immunization with CII.
Cytokine secretion, cell recovery, and proliferation
Cytokines were measured by ELISA [15]. T-cell survival
in vitro was determined by trypan blue exclusion. Cell
proliferation was measured by incorporation of 5-bromo-
2-deoxyuridine (BrdU) (Invitrogen Corporation) over-
night, staining with anti-BrdU, and analysis by flow
cytometry. Alternatively, incorporation of [3H] thymidine
(1 μCi/well; PerkinElmer Inc., Boston, MA, USA) during
the last 12 hours of culture was measured.
Immunoblotting
Live CD4+ T cells were lysed in ice-cold RIPA lysis buffer
(20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM
Na3VO4, and 1 μg/mL leupeptin) for 30 minutes. Insolu-
ble material was removed by centrifugation, and lysates
were used for Western blotting. Protein content was
determined by a Bio-Rad protein assay kit (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA). Equal amounts of pro-
tein (40 μg) were loaded onto 4% to 12% NuPage Bis-Tris
precasting gels and separated by SDS-PAGE, transferred
onto nitrocellulose membrane (Invitrogen Corporation),
and immunoblotted. All blots were developed with the
ECL (enhanced chemiluminescence) immunodetection
system (Amersham Pharmacia Biotech, now part of GE
Healthcare, Little Chalfont, Buckinghamshire, UK).
Results
Expression of FoxP3 and Bcl-xL using 2A gene sequence in 
primary CD4+ T cells
Previously, we used the 2A peptide regions from picorna-
virus TaV (abbreviated herein as T2A) to generate multi-
cistronic cassettes that linked Bcl-xL and survivin to
make a single fragment encoding two proteins [18]. To
generate reliable and versatile constructs to transduce
primary CD4+ T cells that permit expression of FoxP3
and Bcl-xL genes, we used the T2A peptide to generate a
retroviral vector with efficient translation of two cistrons
(for example, FoxP3 and Bcl-xL) (Figure 1a). The human
Bcl-xL gene and T2A were excised from Mig-Bcl-xL-2A-
survivin [18] and subcloned into Mig-FoxP3. Thus, Bcl-
xL and FoxP3 were linked with the 2A sequence in the
Mig vector. The integrity of the Mig-Bcl-xL-2A-FoxP3
construct was confirmed by DNA sequencing (data not
shown), and protein expression was verified by Western
blot (Figure 1b). Both Bcl-xL expression and FoxP3
expression were induced by retroviral infection of CD4+
T cells following transduction with retroviral constructs
expressing the individual genes or both genes (Figure 1b).
By this method, approximately half of the cultured CD4+
T cells were induced to express FoxP3 following retrovi-
rus-mediated transduction as visualized by flow cytome-
try (Figure 1c).
FoxP3 and Bcl-xL promote sustained survival of Tregs in 
vitro
To determine whether induced co-expression of FoxP3
and Bcl-xL promotes the persistence of Tregs, we trans-Haque et al. Arthritis Research & Therapy 2010, 12:R66
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duced naive CD4+ T cells with the GFP-IRES (GFP-inter-
nal ribosome entry site) retroviral vector containing
FoxP3 and Bcl-xL (Mig-Bcl-xL-2A-FoxP3) (Figure 2a).
After 2 to 3 days of transduction, the recovery of live T
cells was monitored by GFP expression. On day 4 post-
transduction, we found that the expansion of CD4+ T
cells that had been transduced with both FoxP3 and Bcl-
xL was greater than the expansion of cells transduced
with FoxP3 alone (Figure 2b). Longer-term culture over 8
days showed that co-expression of FoxP3 and Bcl-xL
enhanced the ability of CD4+ T cells to survive as com-
pared with that of CD4+ T cells transduced with FoxP3
alone (Figure 2b). This result was not due to differences
in FoxP3 expression between cells transduced with both
FoxP3 and Bcl-xL versus FoxP3 alone, indicating that
exogenous Bcl-xL did not affect FoxP3 expression (Figure
1b). Moreover, expression of CD25, a marker for Tregs,
was significantly upregulated by day 4 in the CD4+ GFP+
T cells that were transduced with FoxP3 or with FoxP3
plus Bcl-xL as compared with cells in the vector control
group, suggesting that these cells were characteristic of
Tregs after gene transfection (Figure 2c). Similar profiles
were observed in the expression of cytotoxic T-lympho-
cyte-associated molecule-4 (CTLA-4) (data not shown).
Thus, co-expression of FoxP3 and Bcl-xL induced from a
single retroviral vector produced a Treg phenotype in the
resulting cells and provided increased long-term survival
of these cells.
FoxP3 and Bcl-xL enhance the suppressive activity of Tregs 
in vitro
To investigate whether co-expression of FoxP3 and Bcl-
xL promotes suppressive activity of Tregs, CD4+ T cells
expressing FoxP3 and Bcl-xL from primary cultures were
sorted based on GFP expression, and equal numbers of
cells were re-stimulated with anti-CD3 plus anti-CD28
antibodies. Greater numbers of cells were recovered over
time from Tregs derived from expression of both FoxP3
and Bcl-xL as compared with cells transduced with FoxP3
alone (Figure 3a). To evaluate Treg function, Tregs iso-
lated from CD4+ T cells expressing both FoxP3 and Bcl-
xL or FoxP3 alone were co-cultured with naive CD4+ T
cells (Tregs/T cells = 1:1) in the presence of anti-CD3 and
anti-CD28 antibodies for various periods of time. The
results show that production of IL-2 and IFN-γ over the
48-hour period was significantly decreased in the pres-
ence of Tregs derived from expression of FoxP3 alone or
FoxP3 plus Bcl-xL (Figure 3b). However, the proliferation
in CD4+  GFP- T cells was significantly suppressed by
Tregs co-expressing FoxP3 and Bcl-xL as compared with
cells expressing FoxP3 alone on day 4 but not day 2 (Fig-
ure 3c, d). These data indicate that the transduction of
both FoxP3 and Bcl-xL sustains suppressive activity of
CD4+ T cell-derived Tregs by promoting survival advan-
tage.
Figure 1 Expression of FoxP3 and Bcl-xL using a 2A gene sequence in primary CD4+ T cells. (a) Schematic representation of the retrovirus con-
struct expressing Bcl-xL and FoxP3. ψ, packaging signal; 2A, picornavirus self-cleaving 2A sequence. (b) Naive CD4+ T cells from C57BL/6J mice were 
stimulated with anti-CD3 plus anti-CD28 antibodies. On day 2/3, T cells were transduced with retroviral vectors expressing green fluorescent protein 
(GFP) (Mig), GFP with FoxP3 (Mig-FoxP3), GFP with Bcl-xL (Mig-Bcl-xL), or GFP with Bcl-xL and FoxP3 (Mig-Bcl-xL-2A-FoxP3). On day 8 of primary culture, 
GFP+ CD4+ T cells were sorted, and protein expression of FoxP3, Bcl-xL, and β-actin was determined by Western blotting. Data are representative of 
three independent experiments. (c) Intracellular FoxP3 expression on day 6 of primary culture was analyzed by flow cytometry after gating on live 
CD4+ T cells. Data are representative of three independent experiments.Haque et al. Arthritis Research & Therapy 2010, 12:R66
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FoxP3 and Bcl-xL sustain survival of Tregs in vivo
We reported previously that induced expression of Bcl-xL
significantly sustained T-cell survival [15,22]. In the pres-
ent study, we examined whether co-expression of Bcl-xL
with FoxP3 is capable of increasing the persistence of
Tregs  in vivo. CD4+ T cells from OT-II TCR transgenic
mice were induced to differentiate into Tregs by trans-
duction of FoxP3 alone or FoxP3 and Bcl-xL. On day 6
post-transduction, GFP+ Tregs were sorted and adop-
tively transferred into syngeneic recipient mice. These
mice were subsequently challenged with OVA protein.
We found that the effect of Bcl-xL and FoxP3 was cooper-
ative and long-lasting as we measured greater numbers of
Tregs expressing both genes than cells derived by FoxP3
transduction alone on days 7 and 14 after Ag challenge
(Figure 4). Thus, Tregs were maintained above back-
ground levels beyond the time of normal T-cell contrac-
tion (Figure 4). Overall, these data strongly support the
conclusion that the combined activities of FoxP3 and Bcl-
xL promote both the differentiation and long-term sur-
vival of Tregs.
Adoptive cell transfer of FoxP3 plus Bcl-xL-transduced 
Tregs prevents the development of collagen-induced 
arthritis
To demonstrate that the gene transduction of FoxP3 and
Bcl-xL sustains the Treg response in a physiologically and
clinically relevant setting, GFP-sorted Tregs derived from
DBA/1J mice were adoptively transferred into male DBA/
1J mice (>4 months of age). Fifteen days prior to adoptive
transfer (day 0), CIA was induced in the recipient DBA/1J
mice by one intradermal immunization in the base of the
tail with 100 μg of CII in CFA, containing 5 mg/mL killed
Mycobacterium tuberculosis (H37Ra). Arthritis incidence
(Figure 5a) and clinical score (Figure 5b) were assessed in
the paws from three independent experiments (Addi-
tional files 1 and 2). Mice receiving FoxP3-plus-Bcl-xL-
transduced Tregs had a significantly decreased incidence
of arthritis compared with mice receiving Tregs trans-
duced with FoxP3 alone (32% versus 70% on day 60; Fig-
ure 5a). Most importantly, mice receiving FoxP3-plus-
Bcl-xL-transduced Tregs had a lower clinical score than
those receiving Tregs transduced with FoxP3 alone (a
score of 1.2 versus 2.8 on day 60; Figure 5b).
We also examined whether disease severity correlates
with antibody production and histological observations
of the joints. We found that mice receiving FoxP3-plus-
Bcl-xL-transduced Tregs had similar levels of total IgG
and anti-CII IgG1 in the serum as mice that received
Tregs transduced with FoxP3 alone (Figure 6a, b). How-
ever, anti-CII IgG2a was significantly decreased following
adoptive transfer of FoxP3-plus-Bcl-xL-transduced Tregs
(Figure 6c). These results are similar to observations
reported in a recent study that describes decreased levels
of IgG2a following adoptive transfer of Tregs [23].
Because anti-CII IgG2a was the major component of
Figure 2 Retrovirus-mediated transduction of FoxP3 and Bcl-xL promotes survival of regulatory T cells in vitro. Naive CD4+ T cells from C57BL/
6J mice were stimulated with anti-CD3 plus anti-CD28 antibodies, transduced on days 2/3 with retroviral vectors expressing green fluorescent protein 
(GFP), GFP with FoxP3, or GFP with Bcl-xL and FoxP3, and then recultured without any further stimulation. (a) Live CD4+ GFP+ T cells were visualized 
by flow cytometry on day 6 of culture. Data are representative of three independent experiments. (b) GFP+ T-cell recovery was normalized to take into 
account differences in initial transduction efficiency between cultures. Numbers of GFP+ cells present on day 2 were assigned a value of 100%, and 
numbers surviving on days 4, 6, and 8 were used to calculate the percentage recovery relative to day 2. Data represent the mean percentage change 
± standard deviation from three separate experiments (*P <0.05, Student unpaired t test). (c) CD25 expression on day 4 of primary culture was analyzed 
by flow cytometry after gating on live GFP+ CD4+ T cells. Data are representative of three independent experiments.
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anti-CII IgG on day 60, total anti-CII IgG in this case was
significantly reduced by the treatment of adoptive trans-
fer of FoxP3-plus-Bcl-xL-transduced Tregs. These results
are similar to observations previously reported [24,25].
The preventive effects of Treg transfer on CIA were also
confirmed by histological analyses. In the control mice,
there were significant signs of arthritic pathology as
indicted by destruction of cartilage with fibrosis and leu-
kocyte infiltration around bones and in the joint space on
day 60 (Figure 7a). In contrast, the treatment of adoptive
cell transfer of Tregs resulted in a marked suppression of
these symptoms that are characteristic of CIA. In addi-
tion, there were only a few foci of leukocyte infiltration
and less destruction of bones and joints in mice that
received FoxP3-plus-Bcl-xL-transduced Tregs (Figure 7).
Collectively, these findings show that the expression of
FoxP3 and Bcl-xL by retrovirus-mediated transduction
can cooperatively promote the persistence of Tregs and
that these Tregs can effectively prevent the development
of CIA.
Discussion
Signals from TCR or co-stimulatory molecules such as
CD28, 4-1BB, and ICOS or both have been shown to pro-
mote expression of Bcl-xL, which controls T-cell survival,
and maintain expression of FoxP3, which sustains sup-
pressive activities of Tregs [10,12,26-30]. In addition,
naive CD4+ T cells have the ability to differentiate into
Tregs by gene transduction of FoxP3 [2-4], and FoxP3
transgenic mice are resistant to CIA via reduced prolifer-
Figure 3 Retrovirus-mediated transduction of FoxP3 and Bcl-xL enhances suppressive activity of regulatory T cells (Tregs) in vitro. Naive 
CD4+ T cells from C57BL/6J mice were stimulated with anti-CD3 plus anti-CD28 antibodies (Abs). On day 2/3, T cells were transduced with retroviral 
vectors expressing green fluorescent protein (GFP), GFP with FoxP3, or GFP with Bcl-xL and FoxP3. On day 6 of primary culture, GFP+ CD4+ Tregs were 
sorted and re-stimulated with anti-CD3 and anti-CD28 Abs (a) or co-cultured with naive CD4+ T cells from C57BL/6J mice (Tregs/T cells = 1:1) stimu-
lated with anti-CD3 and anti-CD28 Abs for various periods (b, c). (a) Recall survival of Tregs, based on recovery of GFP+ CD4+ T cells over time. Cell 
numbers present on day 0 were assigned a value of 100%, and cell numbers surviving on day 2 to day 8 were used to calculate the percentage recov-
ery. Data represent the mean percentage change ± standard deviation from three separate experiments. (b) Interleukin-2 (IL-2) production and inter-
feron-gamma (IFN-γ) production were measured by enzyme-linked immunosorbent assay at 48 hours. Data are representative of three independent 
experiments. Proliferation on day 2 or 4 was analyzed by flow cytometry for 5-bromo-2-deoxyuridine (BrdU) incorporation (c) and thymidine incorpo-
ration during the last 12 hours (d). Data are representative of three experiments. *P <0.05, Student unpaired t test.
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ation of activated T cells [31]. Moreover, it has been
shown that adoptive cell transfer of Tregs can suppress
arthritis [24,32]. Therefore, we tested the hypothesis that
co-transduction of CD4+ T cells with both FoxP3 and Bcl-
xL will generate highly reactive Tregs that can be used to
prevent autoimmune disease. In this study, we show that
(a) co-expression of FoxP3 and Bcl-xL is able to contrib-
ute in a cooperative manner to augment the accumula-
tion and persistence of Tregs and (b) these Tregs
efficiently prevent the onset of CIA in vivo.
To induce the simultaneous and equal expression of
two exogenous proteins in CD4+ T cells, we used the
picornavirus self-cleaving T2A sequence to link genes
encoding FoxP3 and Bcl-xL. The 2A-like sequences are
small (54 base pairs [bp] in T2A), making multiple cis-
tronic constructs ideal for use in size-restricted viral and
non-viral vectors and promoting equal and coupled
expression of several genes (total size of less than 4,000
bp) [33,34], as we have documented here. We previously
reported that cooperation between molecular targets of
co-stimulation promotes T-cell persistence and tumor
regression [18]. In that study, also using the picornavirus
2A sequence, we linked Bcl-xL and survivin in a retroviral
vector that permitted their equal expression in primary T
cells. Our results showed that, by using this 2A sequence,
Bcl-xL and survivin were concomitantly expressed in pri-
mary CD8+ T cells after retrovirus-mediated transduc-
tion. Furthermore, Bcl-xL and survivin cooperated to
sustain T-cell division and survival over time, and hence
we concluded that they coordinately regulate the extent
of clonal expansion of primary effector and memory
effector T cells. In the present study, using the 2A
sequence and a similar approach, we found that FoxP3
and Bcl-xL can also cooperatively promote differentiation
and persistence of Tregs, resulting in the prevention of
arthritis development.
Tregs develop in the thymus and are identified by their
high levels of CD4, CD25, and FoxP3 and also their low
expression of CD127 [35,36]. Expression of FoxP3 is
required for Treg development and appears to control cell
fate [19]. In the peripheral lymphoid organs, the large
majority of FoxP3-expressing Tregs are found within the
major histocompatibility complex (MHC) class II-
restricted CD4-expressing (CD4+) helper T-cell popula-
tion and express high levels of the IL-2 receptor alpha
chain (CD25). In addition to the FoxP3-expressing
CD4+CD25+ Tregs, there appears to be a minor popula-
tion of MHC class I-restricted CD8+ FoxP3-expressing
Tregs. Because CD25 is also expressed on activated T
cells, the regulatory T-cell population is more accurately
defined by FoxP3 expression. Typically, high levels of
CTLA-4 and glucocorticoid-induced TNF receptor
(GITR) are also expressed on Tregs [37-39], but the func-
tional significance of this expression remains to be
defined. There is great interest in identifying cell surface
markers that are uniquely and specifically expressed on
all FoxP3-expressing Tregs. However, to date, no such
molecules have been identified.
FoxP3-expressing Tregs are crucial mediators of
peripheral tolerance-suppressing autoimmune responses.
Induced expression of FoxP3 confers a Treg phenotype to
conventional T cells, allowing these Tregs to be used
therapeutically for the prevention of autoimmunity and
transplant rejection. Several groups have investigated the
potential use of Tregs in the treatment of arthritis and
their results indicate that adoptive cell transfer of Tregs
can be used therapeutically in arthritis, such as CIA
[24,32,40,41]. A single transfer of CD4+CD25+ T cells
from spleens markedly slowed CIA progression, which
could not be attributed to losses of systemic type II colla-
gen-specific T- and B-cell responses [24]. Similarly, adop-
tive cell transfer of CD4+CD25+ T cells from spleens and
lymph nodes into immunized mice at the time of induc-
tion of CIA decreased the severity of disease but was not
able to cure established arthritis [32]. Moreover, adoptive
cell transfer of FoxP3-transduced Tregs significantly sup-
pressed the progression of established CIA [40,41]. It has
Figure 4 Retrovirus-mediated transduction of FoxP3 and Bcl-xL 
sustains survival of regulatory T cells in vivo. Naive CD4+ T cells 
from OT-II T-cell receptor transgenic mice were stimulated with pep-
tide/antigen-presenting cells. On day 2/3, T cells were transduced with 
retroviral vectors expressing green fluorescent protein (GFP), GFP with 
Bcl-xL, GFP with FoxP3, or GFP with Bcl-xL and FoxP3. On day 6 of pri-
mary culture, 2 × 106 GFP+ CD4+ T cells were sorted and adoptively 
transferred into naive recipient mice that were subsequently chal-
lenged intraperitoneally with whole ovalbumin (OVA) protein (100 μg) 
in phosphate-buffered saline (PBS) (filled bars) or with PBS alone (open 
bars). On days 7 and 14, GFP+ CD4+ T cells were enumerated from 
pooled lymph nodes and spleen. Data are mean number of GFP+ CD4+ 
± standard error of the mean from four individual mice and represen-
tative of three independent experiments (*P <0.05, Student unpaired t 
test).
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been suggested that the timing of Treg transfer should
precede immunization in order to obtain better results
since late-stage aggressive arthritis is more resistant to
Treg transfer [32,41].
We considered that resistance to Treg transfer is due to
Treg apoptosis. In some disease conditions, such as can-
cer and arthritis, Tregs were significantly more sensitive
to apoptosis than normal conventional T cells (for exam-
ple, non-Tregs) [42-45]. Thus, the combination of
increasing the Treg number and decreasing their sensitiv-
ity to apoptosis may benefit clinical uses of Tregs for
autoimmune diseases.
Figure 5 Adoptive cell transfer of FoxP3- and Bcl-xL-transduced regulatory T cells suppresses collagen-induced arthritis (CIA). Naive CD4+ 
T cells from DBA/1J mice were stimulated with anti-CD3 plus anti-CD28 antibodies. On days 2 and 3, the cells were transduced with retroviral con-
structs: vector (Mig), FoxP3 (Mig-FoxP3), or FoxP3 with Bcl-xL (Mig-Bcl-xL-2A-FoxP3). On day 6, green fluorescent protein-positive (GFP+) T cells were 
sorted and prepared for adoptive cell transfer. CIA was induced in male DBA/1J mice (>4 months old) by one (day 0) intradermal immunization in the 
base of the tail with 100 μg of bovine type II collagen in complete Freund's adjuvant, containing 5 mg/mL killed Mycobacterium tuberculosis (H37Ra). 
On day 15 after the immunization, the mice received transduced GFP+ cells (2.5 × 106 per mouse, six mice per group). In the following days, the arthritis 
incidence (a) and clinical score (b) were evaluated by examining the paws and using a 4-point scale: 0, normal paw; 1, minimal swelling or redness; 
2, redness and swelling involving the entire forepaw; 3, redness and swelling involving the entire limp; 4, joint deformity or ankylosis or both. Values 
are the mean ± standard error of the mean of data obtained in three experiments, and in each experiment, six mice per group were used. Summaries 
of the incidences and the mouse arthritis scores of the three experiments are listed in Additional files 1 and 2.
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Figure 6 Adoptive cell transfer of FoxP3- and Bcl-xL-transduced regulatory T cells decreases arthritis-specific antibody production. The 
treatment of adoptive cell transfer for collagen-induced arthritis is described in the legend of Figure 5. On day 60 of immunization, sera were separated 
from all samples and the levels of serum total IgG and anti-bovine type II collagen antibodies were determined by enzyme-linked immunosorbent 
assay. (a) Total IgG. (b) IgG1. (c) IgG2a. Values are the mean ± standard error of the mean (n = 6). Data are representative of two similar experiments 
(*P <0.05, Student unpaired t test). OD, optical density.
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Tregs are highly susceptible to apoptosis in the absence
of common gamma chain (γc) cytokines (for example, IL-
2, IL-4, IL-7, IL-9, IL-15, and IL-21) because they do not
produce these cytokines [46,47]. In addition, Tregs are
susceptible to apoptosis due to low expression of the anti-
apoptotic Bcl-2 family members [48]. FoxP3 transduction
by itself has a detrimental effect on expansion and sur-
vival of CD4+ T cells. Our data show CD4+ T cells trans-
duced by FoxP3 alone had lower cell recovery both in
vitro and in vivo in comparison with vector control-trans-
duced cells (Figures 3 and 4). This defect was then cor-
rected by expression of Bcl-xL. Bcl-xL is an anti-
apoptotic factor that could prolong the life span of apop-
tosis-prone lymphocytes. We used this approach to gen-
erate therapeutically reactive Tregs with an increased life
span and hence greater therapeutic potential than was
achieved by Foxp3 expression alone (Figures 6 and 7).
Thus, the FoxP3 and Bcl-xL-transuced Tregs that we gen-
erated in this study are more efficacious than unmanipu-
lated naturally occurring Tregs.
In this study, we induced highly reactive Tregs from
CD4+  T cells by retrovirus-mediated introduction of
FoxP3 and Bcl-xL. This approach promoted Treg differ-
entiation and long-term survival, resulting in long-lasting
Treg persistence. In addition, adoptive cell transfer of
these highly reactive Tregs prevented the development of
arthritis in a murine model. These data provide new
insights toward the generation of highly reactive Tregs for
adoptive immunotherapy of autoimmune disease. How-
ever, adoptive cell transfer did not cure established arthri-
tis, which might be explained by the absence of specificity
that directs the movement of Tregs to the inflamed paw
[25,40,49]. Thus, generation of antigen-specific highly
reactive Tregs may be a promising approach for the treat-
ment of established autoimmune disease.
Conclusions
The results of the present study demonstrate that FoxP3
and Bcl-xL can cooperatively promote the differentiation
and persistence of Tregs, thereby resulting in prevention
of arthritis. The data suggest a potential novel approach
to generate highly reactive Tregs for augmenting cellular
immunotherapy for autoimmune disease.
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arthritis scores of three experiments.
Figure 7 Adoptive cell transfer of Bcl-xL- and FoxP3-transduced regulatory T cells reduces paw inflammation. The protocol of adoptive cell 
transfer for collagen-induced arthritis is described in the legend of Figure 5. On day 60 of immunization, hind foot paws were amputated, fixed, and 
decalcified. The tissues were embedded in paraffin, sectioned, and stained. (a) Hematoxylin and eosin (HE) staining. (b) HE semiquantitative score. (c) 
Safranin O-fast green staining. (d) Safranin O-fast green semiquantitative score. Data are representative of two similar experiments (*P <0.05, Student 
unpaired t test).
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